A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

Abbott0 sites75 target enrollmentJanuary 2002

ConditionsEnd Stage Renal Disease

Interventionsparicalcitol capsules

Drugsparicalcitol capsules

Overview

Phase: Phase 3
Intervention: paricalcitol capsules
Conditions: End Stage Renal Disease
Sponsor: Abbott
Enrollment: 75
Primary Endpoint: The achievement of two consecutive greater than or equal to 30% decreases from baseline iPTH levels.
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis.

Registry

clinicaltrials.gov

Start Date

January 2002

End Date

November 2002

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Abbott

Eligibility Criteria

Inclusion Criteria

•Subject is greater than or equal to 18 years.
•Subject is diagnosed with ESRD and must be on continuous PD 7 days per week for at least 2 months prior to Screening Phase.
•If female, subject is either not of childbearing potential or is of childbearing potential and practicing one of the recommended methods of birth control.
•If female, subject must have a negative serum pregnancy test prior to treatment.
•If female, subject is not breastfeeding.
•Subject is undergoing full PD regimen and is expected to remain on this PD regimen for the duration of the study.
•For those subjects who have been taking a phosphate binder prior to therapy, the subject has been on a stable type of phosphate binder at least 4 weeks prior to the Pre-Treatment Phase.
•For entry into the Pretreatment Phase the subject must have: Calcium level less than or equal to 10.5 mg/dL and Ca x P level less than or equal to
•For entry into the Treatment Phase the subject must have: iPTH greater than or equal to 300 pg/mL, calcium level of 8.0 to 10.5 mg/dL, inclusive, and Ca x P less than or equal to
•Subject has voluntarily signed and dated an IRB approved informed consent.

Exclusion Criteria

•Subject has history of an allergic reaction or significant sensitivity to drugs similar to the study drug
•Subject has had active peritonitis within 1 month prior to screening phase.
•Subject has had more than one episode of peritonitis within 4 months prior to screening phase.
•Subject has received a partial parathyroidectomy within 1 year prior to screening phase.
•Subject has had acute renal failure within 3 months of screening phase.
•Subject has chronic gastrointestinal disease.
•Subject has taken aluminum-containing phosphate binders for greater than 3 weeks in the last 3 months prior to the screening phase or will require these medications greater than 3 weeks in the study.
•Subject has a current malignancy or clinically significant liver disease.
•Subject has a history of drug or alcohol abuse within 6 months prior to screening phase.
•Subject has evidence of poor compliance with diet, medication, or PD.